HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
38:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
ACE – angiotensin-converting enzyme; CNs – central nervous system; CV – cardiovascular; NO – nitric oxide; :@0.207135:0.645298:0.823778:0.645298:0.823778:0.633023:0.207135:0.633023:0.008702:0.009560:0.006303:0.003257:0.005880:0.003257:0.008032:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.003904:0.007608:0.007702:0.007173:0.006515:0.007644:0.003540:0.003986:0.002352:0.007173:0.007914:0.003257:0.007644:0.007173:0.004998:0.006303:0.011030:0.007644:0.003257:0.003257:0.009560:0.008702:0.005856:0.003257:0.005880:0.003257:0.007608:0.007644:0.007173:0.003986:0.003540:0.008032:0.002352:0.003257:0.007173:0.007644:0.003540:0.006515:0.007702:0.007150:0.004563:0.003257:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.003257:0.003257:0.009560:0.008255:0.003257:0.005880:0.003257:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257:0.003257:0.008702:0.010219:0.003257:0.005880:0.003257:0.007173:0.002352:0.003986:0.003540:0.002352:0.007608:0.003257:0.007702:0.005644:0.002352:0.008055:0.007644:0.003257:0.003257
RAs – renin-angiotensin system; sNs – sympathetic nervous system; R-R – resting rate; :@0.207135:0.656199:0.686512:0.656199:0.686512:0.643924:0.207135:0.643924:0.007138:0.008702:0.005856:0.003257:0.005880:0.003257:0.003540:0.007644:0.007173:0.002352:0.007173:0.003904:0.008032:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.003257:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.003257:0.003257:0.005856:0.008702:0.005856:0.003257:0.005880:0.003257:0.004563:0.006303:0.011030:0.008020:0.008032:0.003986:0.007173:0.007644:0.003986:0.002352:0.007608:0.003257:0.007173:0.007644:0.003540:0.006515:0.007702:0.007150:0.004563:0.003257:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.003257:0.003257:0.007138:0.003904:0.007138:0.003257:0.005880:0.003257:0.003540:0.007644:0.004563:0.003986:0.002352:0.007173:0.007914:0.003257:0.003540:0.008032:0.003986:0.007644:0.003210:0.003257
ROs – reactive oxygen species; VsMC – vascular smooth muscle cells;  – increase,   – decrease:@0.207135:0.667101:0.752164:0.667101:0.752164:0.654825:0.207135:0.654825:0.007138:0.010219:0.005856:0.003257:0.005880:0.003257:0.003540:0.007644:0.008032:0.007608:0.003986:0.002352:0.006515:0.007644:0.003257:0.007702:0.005644:0.006303:0.007914:0.007644:0.007173:0.003257:0.004563:0.008020:0.007644:0.007608:0.002352:0.007644:0.004563:0.003257:0.003257:0.008255:0.005856:0.010807:0.009560:0.003257:0.005880:0.003257:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257:0.004563:0.011030:0.007702:0.007702:0.003986:0.007173:0.003257:0.011030:0.007150:0.004563:0.007608:0.002352:0.007644:0.003257:0.007608:0.007644:0.002352:0.002352:0.004563:0.003257:0.003257:0.009137:0.005880:0.003257:0.002352:0.007173:0.007608:0.003540:0.007644:0.008032:0.004563:0.007644:0.003257:0.003257:0.005868:0.003257:0.005880:0.003257:0.008055:0.007644:0.007608:0.003540:0.007644:0.008032:0.004563:0.007644
↑ :@0.605820:0.667262:0.614969:0.667262:0.614969:0.655005:0.605820:0.655005:0.005880:0.003269
↓:@0.679163:0.667262:0.685043:0.667262:0.685043:0.655005:0.679163:0.655005:0.005880
Adapted from McFarlane :@0.207135:0.692756:0.356254:0.692756:0.356254:0.680481:0.207135:0.680481:0.008702:0.008055:0.008032:0.008020:0.003986:0.007644:0.008055:0.003257:0.003692:0.003540:0.007702:0.011030:0.003257:0.010807:0.007608:0.005703:0.008032:0.003540:0.002352:0.008032:0.007173:0.007644:0.003257
et al:@0.356242:0.692756:0.381513:0.692756:0.381513:0.680481:0.356242:0.680481:0.007644:0.003986:0.003257:0.008032:0.002352
4:@0.381508:0.688641:0.385287:0.688641:0.385287:0.681522:0.381508:0.681522:0.003778
 and sharma :@0.385288:0.692763:0.461982:0.692763:0.461982:0.680487:0.385288:0.680487:0.003257:0.008032:0.007173:0.008055:0.003257:0.005856:0.007173:0.008032:0.003540:0.011030:0.008032:0.003257
et al:@0.461970:0.692763:0.487241:0.692763:0.487241:0.680487:0.461970:0.680487:0.007644:0.003986:0.003257:0.008032:0.002352
7:@0.487246:0.688641:0.491024:0.688641:0.491024:0.681522:0.487246:0.681522:0.003778
figure 1. the role of angiotensin ii in cardiovascular and metabolic dysregulation:@0.076190:0.714204:0.666438:0.714204:0.666438:0.697705:0.076190:0.697705:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.004233:0.004233:0.006350:0.009071:0.009676:0.004233:0.004838:0.009676:0.003629:0.009676:0.004233:0.009676:0.004233:0.004233:0.009979:0.009071:0.009979:0.003629:0.009676:0.004536:0.009676:0.009071:0.006652:0.003629:0.009071:0.004233:0.004233:0.004233:0.004233:0.003629:0.009071:0.004233:0.009676:0.009979:0.004838:0.009979:0.003629:0.009676:0.008467:0.009979:0.006652:0.009676:0.009071:0.003629:0.009979:0.004838:0.004233:0.009979:0.009071:0.009979:0.004233:0.014212:0.009676:0.004536:0.009979:0.009979:0.009676:0.003629:0.003629:0.009676:0.004233:0.009979:0.008769:0.006652:0.004838:0.009676:0.009979:0.009071:0.003629:0.009979:0.004536:0.003629:0.009676:0.009071
and higher doses of ARBs also reduce the risk of HF hos-:@0.076190:0.760386:0.480927:0.760386:0.480927:0.744603:0.076190:0.744603:0.010326:0.009223:0.010357:0.004294:0.009223:0.003024:0.010175:0.009223:0.009827:0.004551:0.004294:0.010357:0.009903:0.005866:0.009827:0.005866:0.004294:0.009903:0.004747:0.004294:0.011188:0.009177:0.008678:0.005866:0.004294:0.010326:0.003024:0.005866:0.009903:0.004309:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004294:0.005125:0.009223:0.009827:0.004294:0.004551:0.003024:0.005866:0.007590:0.004294:0.009903:0.004747:0.004294:0.010326:0.007333:0.004294:0.009223:0.009903:0.005866:0.005020
pitalisation. Giving higher dosages increases the risk of :@0.076190:0.774610:0.485130:0.774610:0.485130:0.758827:0.076190:0.758827:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005866:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.005549:0.013184:0.003024:0.008376:0.003024:0.009223:0.010175:0.005549:0.009223:0.003024:0.010175:0.009223:0.009827:0.004551:0.005534:0.010357:0.009903:0.005866:0.010326:0.010175:0.009827:0.005866:0.005534:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.005866:0.005534:0.005125:0.009223:0.009827:0.005534:0.004551:0.003024:0.005866:0.007590:0.005534:0.009903:0.004747:0.004188
hypotension and adverse effects (e.g. hyperkalaemia, :@0.076190:0.788833:0.485145:0.788833:0.485145:0.773051:0.076190:0.773051:0.009223:0.008104:0.010311:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.005458:0.010326:0.009223:0.010357:0.005458:0.010326:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.005458:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.005458:0.005579:0.009827:0.004188:0.010175:0.004188:0.005458:0.009223:0.008104:0.010311:0.009827:0.004551:0.007590:0.010326:0.003024:0.010326:0.009827:0.014182:0.003024:0.010326:0.004188:0.004188
cough, rise in creatinine and so on), compared to lower :@0.076190:0.803057:0.485130:0.803057:0.485130:0.787275:0.076190:0.787275:0.009782:0.009903:0.009192:0.010175:0.009223:0.004188:0.003780:0.004551:0.003024:0.005866:0.009827:0.003795:0.003024:0.009223:0.003795:0.009782:0.004551:0.009827:0.010326:0.005125:0.003024:0.009223:0.003024:0.009223:0.009827:0.003795:0.010326:0.009223:0.010357:0.003795:0.005866:0.009903:0.003795:0.009903:0.009223:0.005579:0.004188:0.003795:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.003795:0.005125:0.009903:0.003795:0.003024:0.009903:0.012564:0.009827:0.004551:0.004188
dosages. :@0.076190:0.817281:0.146887:0.817281:0.146887:0.801499:0.076190:0.801499:0.010357:0.009903:0.005866:0.010326:0.010175:0.009827:0.005866:0.004188:0.004188
The  renin antagonist,  aliskiren, did not  demonstrate :@0.090478:0.831505:0.485130:0.831505:0.485130:0.815723:0.090478:0.815723:0.006441:0.009223:0.009827:0.004188:0.003084:0.004551:0.009827:0.009223:0.003024:0.009223:0.007287:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.004188:0.004188:0.003084:0.010326:0.003024:0.003024:0.005866:0.007590:0.003024:0.004551:0.009827:0.009223:0.004188:0.007287:0.010357:0.003024:0.010357:0.007287:0.009223:0.009903:0.005125:0.004188:0.003084:0.010357:0.009827:0.014182:0.009903:0.009223:0.005866:0.005125:0.004551:0.010326:0.005125:0.009827:0.004188
any advantage when given alone or  in combination :@0.076190:0.845729:0.485145:0.845729:0.485145:0.829947:0.076190:0.829947:0.010326:0.009223:0.008104:0.006940:0.010326:0.010357:0.008376:0.010326:0.009223:0.005125:0.010326:0.010175:0.009827:0.006940:0.012564:0.009223:0.009827:0.009223:0.006940:0.010175:0.003024:0.008376:0.009827:0.009223:0.006940:0.010326:0.003024:0.009903:0.009223:0.009827:0.006940:0.009903:0.004551:0.004188:0.002737:0.003024:0.009223:0.006940:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
with an ACEI for heart failure. In patients with chronic :@0.076190:0.859953:0.485160:0.859953:0.485160:0.844171:0.076190:0.844171:0.012564:0.003024:0.005125:0.009223:0.006259:0.010326:0.009223:0.006244:0.011188:0.012292:0.008104:0.003417:0.006259:0.004747:0.009903:0.004551:0.006244:0.009223:0.009827:0.010326:0.004551:0.005125:0.006244:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.006244:0.003417:0.009223:0.006259:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006259:0.012564:0.003024:0.005125:0.009223:0.006259:0.009782:0.009223:0.004551:0.009903:0.009223:0.003024:0.009782:0.004188
heart  failure,  the  addition  of  aliskiren to  enalapril led :@0.076190:0.874177:0.485130:0.874177:0.485130:0.858395:0.076190:0.858395:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188:0.003099:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.004188:0.003099:0.005125:0.009223:0.009827:0.004188:0.003099:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.004188:0.003099:0.009903:0.004747:0.004188:0.003099:0.010326:0.003024:0.003024:0.005866:0.007590:0.003024:0.004551:0.009827:0.009223:0.007302:0.005125:0.009903:0.004188:0.003099:0.009827:0.009223:0.010326:0.003024:0.010326:0.010311:0.004551:0.003024:0.003024:0.007302:0.003024:0.009827:0.010357:0.004188
to more adverse events without an increase in benefit. :@0.076190:0.888401:0.485160:0.888401:0.485160:0.872619:0.076190:0.872619:0.005125:0.009903:0.004959:0.014182:0.009903:0.004551:0.009827:0.004959:0.010326:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.004959:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004959:0.012564:0.003024:0.005125:0.009223:0.009903:0.009192:0.005125:0.004959:0.010326:0.009223:0.004959:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.004959:0.003024:0.009223:0.004959:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004188:0.004188
Non-inferiority  was not  shown for  aliskiren when  com-:@0.076190:0.902625:0.480942:0.902625:0.480942:0.886843:0.076190:0.886843:0.011188:0.009903:0.009223:0.005020:0.003024:0.009223:0.004747:0.009827:0.004551:0.003024:0.009903:0.004551:0.003024:0.005125:0.008104:0.004188:0.002827:0.012564:0.010326:0.005866:0.007030:0.009223:0.009903:0.005125:0.004188:0.002827:0.005866:0.009223:0.009903:0.012564:0.009223:0.007030:0.004747:0.009903:0.004551:0.004188:0.002827:0.010326:0.003024:0.003024:0.005866:0.007590:0.003024:0.004551:0.009827:0.009223:0.007030:0.012564:0.009223:0.009827:0.009223:0.004188:0.002827:0.009782:0.009903:0.014182:0.005020
pared to enalapril.  :@0.076190:0.916849:0.221834:0.916905:0.221834:0.901122:0.076190:0.901067:0.010311:0.010326:0.004551:0.009827:0.010357:0.004188:0.005125:0.009903:0.004188:0.009827:0.009223:0.010326:0.003024:0.010326:0.010311:0.004551:0.003024:0.003024:0.004188:0.004855:-0.088162
4:@0.212786:0.911606:0.217644:0.911606:0.217644:0.902452:0.212786:0.902452:0.004858
In a systematic review, the authors  point out that :@0.090479:0.931129:0.485147:0.931129:0.485147:0.915346:0.090479:0.915346:0.003417:0.009223:0.008497:0.010326:0.008497:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.010326:0.005125:0.003024:0.009782:0.008497:0.004551:0.009827:0.008376:0.003024:0.009827:0.012564:0.004188:0.008497:0.005125:0.009223:0.009827:0.008497:0.010326:0.009192:0.005125:0.009223:0.009903:0.004551:0.005866:0.004188:0.004294:0.010311:0.009903:0.003024:0.009223:0.005125:0.008497:0.009903:0.009192:0.005125:0.008497:0.005125:0.009223:0.010326:0.005125:0.004188
aliskiren, either used alone or combined with standard :@0.076192:0.945353:0.485132:0.945353:0.485132:0.929570:0.076192:0.929570:0.010326:0.003024:0.003024:0.005866:0.007590:0.003024:0.004551:0.009827:0.009223:0.004188:0.005413:0.009827:0.003024:0.005125:0.009223:0.009827:0.004536:0.005413:0.009192:0.005866:0.009827:0.010357:0.005413:0.010326:0.003024:0.009903:0.009223:0.009827:0.005413:0.009903:0.004551:0.005397:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.009827:0.010357:0.005413:0.012564:0.003024:0.005125:0.009223:0.005413:0.005866:0.005125:0.010326:0.009223:0.010357:0.010326:0.004551:0.010357:0.004188
medication, does not significantly reduce the all-cause :@0.519044:0.760371:0.927983:0.760371:0.927983:0.744589:0.519044:0.744589:0.014182:0.009827:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004536:0.010357:0.009903:0.009827:0.005866:0.004536:0.009223:0.009903:0.005125:0.004536:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.003024:0.008104:0.004551:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004536:0.005125:0.009223:0.009827:0.004536:0.010326:0.003024:0.003024:0.005020:0.009782:0.010326:0.009192:0.005866:0.009827:0.004188
mortality or  cardiovascular mortality of heart-failure :@0.519044:0.775484:0.927998:0.775484:0.927998:0.759702:0.519044:0.759702:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.010160:0.009903:0.004551:0.004188:0.005957:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.010160:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.010160:0.009903:0.004747:0.010160:0.009223:0.009827:0.010326:0.004551:0.005125:0.005020:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188
patients.  Therefore  aliskiren is not  a RAAs  blocker of :@0.519044:0.790597:0.927978:0.790612:0.927978:0.774830:0.519044:0.774815:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.004863:0.007423:0.006441:0.009223:0.009827:0.004551:0.009812:0.004747:0.009903:0.004551:0.009827:0.004188:0.003220:0.010326:0.003024:0.003024:0.005866:0.007590:0.003024:0.004551:0.009827:0.009223:0.007423:0.003024:0.005866:0.007423:0.009223:0.009903:0.005125:0.004188:0.003220:0.010326:0.007423:0.009177:0.011188:0.011188:0.007529:0.004188:0.003220:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.007423:0.009903:0.004747:-0.628924
5:@0.582063:0.785314:0.586921:0.785314:0.586921:0.776160:0.582063:0.776160:0.004858
choice, either alone or in combination with other RAAs :@0.519053:0.805725:0.927993:0.805725:0.927993:0.789943:0.519053:0.789943:0.009782:0.009223:0.009903:0.003024:0.009782:0.009827:0.004188:0.004596:0.009827:0.003024:0.005125:0.009223:0.009827:0.004551:0.004596:0.010326:0.003024:0.009903:0.009223:0.009827:0.004596:0.009903:0.004551:0.004596:0.003024:0.009223:0.004596:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.004596:0.012564:0.003024:0.005125:0.009223:0.004596:0.009903:0.005125:0.009223:0.009827:0.004551:0.004596:0.009177:0.011188:0.011188:0.007529:0.004188
antagonists.:@0.519053:0.820838:0.607424:0.820838:0.607424:0.805056:0.519053:0.805056:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.005866:0.004188
myOCArDiAl infArCtiOn :@0.519047:0.854443:0.760381:0.854443:0.760381:0.834279:0.519047:0.834279:0.016631:0.011457:0.015522:0.014413:0.013674:0.010718:0.012935:0.005174:0.013674:0.008131:0.005174:0.005174:0.013674:0.008870:0.013674:0.010718:0.014413:0.007761:0.005174:0.015522:0.013674:0.005174
Guidelines indicate the role of ACEIs in the prevention :@0.519047:0.871078:0.927972:0.871078:0.927972:0.855296:0.519047:0.855296:0.013184:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.005594:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.005594:0.005125:0.009223:0.009827:0.005579:0.004551:0.009903:0.003024:0.009827:0.005579:0.009903:0.004747:0.005579:0.011188:0.012292:0.008104:0.003417:0.005866:0.005594:0.003024:0.009223:0.005594:0.005125:0.009223:0.009827:0.005579:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.004188
of  myocardial infarction  (MI), especially in patients :@0.519047:0.885937:0.927987:0.885937:0.927987:0.870155:0.519047:0.870155:0.009903:0.004747:0.004188:0.005927:0.014182:0.008104:0.009903:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.010130:0.003024:0.009223:0.004747:0.010326:0.004551:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.005927:0.005579:0.013894:0.003417:0.005579:0.004188:0.010130:0.009827:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.008104:0.010130:0.003024:0.009223:0.010130:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188
post-MI and in patients with poor left ventricular func-:@0.519047:0.900796:0.923829:0.900796:0.923829:0.885014:0.519047:0.885014:0.010311:0.009903:0.005866:0.005125:0.005020:0.013894:0.003417:0.006002:0.010326:0.009223:0.010357:0.006002:0.003024:0.009223:0.006002:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006002:0.012564:0.003024:0.005125:0.009223:0.006002:0.010311:0.009903:0.009903:0.004551:0.005987:0.003024:0.009827:0.004747:0.005125:0.005987:0.008376:0.009827:0.009223:0.005125:0.004551:0.003024:0.009782:0.009192:0.003024:0.010326:0.004551:0.005987:0.004747:0.009192:0.009223:0.009782:0.005020
tion. Early controversy existed over the use of ARBs in the :@0.519047:0.915655:0.928002:0.915655:0.928002:0.899873:0.519047:0.899873:0.005125:0.003024:0.009903:0.009223:0.004188:0.003492:0.008104:0.010326:0.004551:0.003024:0.008104:0.003508:0.009782:0.009903:0.009223:0.005125:0.004536:0.009903:0.008376:0.009827:0.004551:0.005866:0.008104:0.003508:0.009827:0.007257:0.003024:0.005866:0.005125:0.009827:0.010357:0.003508:0.009903:0.008376:0.009827:0.004551:0.003492:0.005125:0.009223:0.009827:0.003492:0.009192:0.005866:0.009827:0.003508:0.009903:0.004747:0.003492:0.011188:0.009177:0.008678:0.005866:0.003508:0.003024:0.009223:0.003508:0.005125:0.009223:0.009827:0.004188
same setting. The reason being that AT blockade results :@0.519047:0.930514:0.927990:0.930506:0.927990:0.914723:0.519047:0.914732:0.005866:0.010326:0.014182:0.009827:0.003613:0.005866:0.009827:0.005125:0.005125:0.003024:0.009223:0.010175:0.004188:0.003613:0.006441:0.009223:0.009827:0.003613:0.004551:0.009827:0.010326:0.005866:0.009903:0.009223:0.003613:0.010311:0.009827:0.003024:0.009223:0.010175:0.003613:0.005125:0.009223:0.010326:0.005125:0.003613:0.011188:0.006441:0.006958:0.010311:0.003024:0.009903:0.009782:0.007590:0.010326:0.010357:0.009827:0.003613:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.005866:-0.812130
1 :@0.798658:0.930172:0.805945:0.930172:0.805945:0.921018:0.798658:0.921018:0.004858:0.002429
in upregulation of angiotensin II production and stimu-:@0.519050:0.945365:0.923787:0.945365:0.923787:0.929582:0.519050:0.929582:0.003024:0.009223:0.005503:0.009192:0.010311:0.004551:0.009827:0.010175:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009207:0.005503:0.009903:0.004747:0.005503:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.005503:0.003417:0.003417:0.005503:0.010311:0.004551:0.009903:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.005503:0.010326:0.009223:0.010357:0.005503:0.005866:0.005125:0.003024:0.014182:0.009192:0.005020